Assessing risk/benefit for trials using preclinical evidence: a proposal
Moral evaluation of risk/benefit in early phase studies requires assessing the clinical promise of a candidate intervention using preclinical evidence. Yet, there is little to guide ethics committees, investigators, sponsors or other stakeholders morally charged with making these assessments (‘evalu...
| Authors: | ; |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | Drawer...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Published: |
BMJ Publ.
2016
|
| In: |
Journal of medical ethics
Year: 2016, Volume: 42, Issue: 1, Pages: 50-53 |
| Online Access: |
Presumably Free Access Volltext (JSTOR) Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |
MARC
| LEADER | 00000caa a22000002 4500 | ||
|---|---|---|---|
| 001 | 1816152749 | ||
| 003 | DE-627 | ||
| 005 | 20230426115836.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220908s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/medethics-2015-102882 |2 doi | |
| 035 | |a (DE-627)1816152749 | ||
| 035 | |a (DE-599)KXP1816152749 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 1 |2 ssgn | ||
| 100 | 1 | |a Kimmelman, Jonathan |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Assessing risk/benefit for trials using preclinical evidence: a proposal |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Moral evaluation of risk/benefit in early phase studies requires assessing the clinical promise of a candidate intervention using preclinical evidence. Yet, there is little to guide ethics committees, investigators, sponsors or other stakeholders morally charged with making these assessments (‘evaluators’). In what follows, we draw on published guidelines for preclinical study design to develop a structured process for assessing the clinical promise of new interventions. In the first step, evaluators gather all relevant preclinical studies, assess the magnitude of treatment effects and determine clinical promise in light of various threats to valid clinical inference. In the second step, evaluators adjust the assessments of clinical promise from preclinical studies by examining how other agents in the same reference class—and supported by similar evidence—have fared in clinical development. Assessments of clinical promise can then be fed into the moral evaluation of risk and benefit in early phase trials. Though our approach has limitations, it offers a systematic and transparent method for assessing risk/benefit in early phase trials of novel interventions. | ||
| 700 | 1 | |a Henderson, Valerie |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical ethics |d London : BMJ Publ., 1975 |g 42(2016), 1, Seite 50-53 |h Online-Ressource |w (DE-627)323607802 |w (DE-600)2026397-1 |w (DE-576)260773972 |x 1473-4257 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2016 |g number:1 |g pages:50-53 |
| 856 | |3 Volltext |u http://www.jstor.org/stable/44014294 |x JSTOR | ||
| 856 | |u https://europepmc.org/articles/pmc4854630?pdf=render |x unpaywall |z Vermutlich kostenfreier Zugang |h repository [oa repository (via OAI-PMH doi match)] | ||
| 856 | 4 | 0 | |u https://doi.org/10.1136/medethics-2015-102882 |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://jme.bmj.com/content/42/1/50.abstract |x Verlag |z lizenzpflichtig |3 Volltext |
| 935 | |a mteo | ||
| 951 | |a AR | ||
| ELC | |a 1 | ||
| ITA | |a 1 |t 1 | ||
| LOK | |0 000 xxxxxcx a22 zn 4500 | ||
| LOK | |0 001 4185606680 | ||
| LOK | |0 003 DE-627 | ||
| LOK | |0 004 1816152749 | ||
| LOK | |0 005 20220908053651 | ||
| LOK | |0 008 220908||||||||||||||||ger||||||| | ||
| LOK | |0 035 |a (DE-Tue135)IxTheo#2022-08-03#9D1BA701D6BB36061864FAEF4072B2AF430EC8DC | ||
| LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
| LOK | |0 092 |o n | ||
| LOK | |0 852 |a DE-Tue135 | ||
| LOK | |0 852 1 |9 00 | ||
| LOK | |0 866 |x JSTOR#http://www.jstor.org/stable/44014294 | ||
| LOK | |0 935 |a ixzs |a ixrk |a zota | ||
| OAS | |a 1 | ||
| ORI | |a SA-MARC-ixtheoa001.raw | ||